Pathogenic Roles of CXCL10 in Experimental Autoimmune Prostatitis by Modulating Macrophage Chemotaxis and Cytokine

Xiaoliang Hua1,2,3, Shengdong Ge1,2,3, Meng Zhang1,2,3

  • 1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Frontiers in Immunology
|October 18, 2021
PubMed

Insights

The CXCL10/CXCR3 pathway drives chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) by promoting macrophage migration and inflammation. Inhibiting this pathway may reduce CP/CPPS severity.

Area of Science:

  • Immunology
  • Urology
  • Cell Biology

Background:

  • Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) involves immune cell infiltration and pain.
  • Macrophages are key players in CP/CPPS pathogenesis, but their regulation is unclear.

Purpose of the Study:

  • To investigate the role of the CXCL10/CXCR3 pathway in macrophage activation and migration in CP/CPPS patients.
  • To explore therapeutic strategies targeting the CXCL10/CXCR3 pathway.

Main Methods:

  • Serum analysis in CP/CPPS patients and healthy controls.
  • Experimental autoimmune prostatitis (EAP) mouse model with genetic and pharmacological interventions (AAV, CXCR3 inhibitors).
  • Immunofluorescence, flow cytometry, and Western blotting to analyze macrophage function.

Main Results:

  • CXCL10 levels were elevated in CP/CPPS patients and correlated with disease severity.
  • CXCL10 deficiency reduced EAP severity by inhibiting macrophage infiltration.
  • CXCL10 induced macrophage migration and pro-inflammatory mediator secretion via CXCR3, activating Erk1/2 and p38 MAPK pathways.
  • Prostatic stromal cells identified as a potential source of CXCL10.

Conclusions:

  • The CXCL10/CXCR3 pathway is crucial in CP/CPPS pathogenesis by mediating macrophage recruitment and activation.
  • Targeting CXCL10/CXCR3 signaling offers a potential therapeutic approach for CP/CPPS.
  • CXCL10 promotes inflammation and pain in prostatitis via CXCR3-mediated MAPK activation.